|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-5-15
|
|
pubmed:abstractText |
The production of therapeutic T-cell populations for adoptive immunotherapy of cancer requires extensive ex vivo cell processing, including the isolation or creation of Ag-specific T cells and their subsequent propagation to clinically relevant numbers. These procedures must be performed according to the principles of current good manufacturing practices (cGMP) for phase I clinical trials to ensure the identity, purity potency and safety of the cellular product. In this report we describe our approach to manufacturing and characterizing bulk populations of gene-modified autologous T cells for use in treating follicular lymphoma.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD19,
http://linkedlifedata.com/resource/pubmed/chemical/Ganciclovir,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Muromonab-CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidine Kinase
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1465-3249
|
|
pubmed:author |
pubmed-author:AusubelLL,
pubmed-author:BurtonLL,
pubmed-author:CooperL J NLJ,
pubmed-author:DiGiustoD LDL,
pubmed-author:FormanS JSJ,
pubmed-author:GutierrezMM,
pubmed-author:JensenM C VMC,
pubmed-author:OlivaresSS,
pubmed-author:SerranoL MLM,
pubmed-author:ShakeleyRR,
pubmed-author:StephanSS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
105-17
|
|
pubmed:dateRevised |
2008-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:16698684-Antigens, CD,
pubmed-meshheading:16698684-Antigens, CD19,
pubmed-meshheading:16698684-Cell Line, Tumor,
pubmed-meshheading:16698684-Cells, Cultured,
pubmed-meshheading:16698684-Cytotoxicity, Immunologic,
pubmed-meshheading:16698684-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:16698684-Ganciclovir,
pubmed-meshheading:16698684-Humans,
pubmed-meshheading:16698684-Immunotherapy, Adoptive,
pubmed-meshheading:16698684-Interleukin-2,
pubmed-meshheading:16698684-Leukocytes, Mononuclear,
pubmed-meshheading:16698684-Linear Models,
pubmed-meshheading:16698684-Lymphoma, Follicular,
pubmed-meshheading:16698684-Muromonab-CD3,
pubmed-meshheading:16698684-Plasmids,
pubmed-meshheading:16698684-Receptors, Antigen, T-Cell,
pubmed-meshheading:16698684-Recombinant Fusion Proteins,
pubmed-meshheading:16698684-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:16698684-Thymidine Kinase,
pubmed-meshheading:16698684-Transfection
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
|
|
pubmed:affiliation |
Division of Pediatric Hematology-Oncology, City of Hope National Medical Center, California 91010, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
